We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Spero Therapeutics Inc | NASDAQ:SPRO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0102 | 0.63% | 1.6302 | 1.63 | 1.65 | 1.65 | 1.59 | 1.60 | 104,436 | 17:57:57 |
As filed with the Securities and Exchange Commission on November 14, 2022
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
SPERO THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 46-4590683 | |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
675 Massachusetts Avenue, 14th Floor Cambridge, Massachusetts |
02139 | |
(Address of Principal Executive Offices) | (Zip Code) |
SPERO THERAPEUTICS, INC. 2017 STOCK INCENTIVE PLAN, AS AMENDED
(Full title of the plan)
Ankit Mahadevia, M.D., Chief Executive Officer and President
Spero Therapeutics, Inc.
675 Massachusetts Avenue, 14th Floor
Cambridge, Massachusetts 02139
(Name and address of agent of service)
(857) 242-1600
(Telephone number, including area code, of agent for service)
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of large accelerated filer, accelerated filer, smaller reporting company, and emerging growth company in Rule 12b-2 of the Exchange Act.
Large accelerated filer | ☐ | Accelerated filer | ☐ | |||
Non-accelerated filer | ☒ | Smaller reporting company | ☒ | |||
Emerging growth company | ☒ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☒
EXPLANATORY NOTE
This registration statement registers an aggregate of 2,000,000 additional shares of common stock of Spero Therapeutics, Inc. (the Registrant) reserved under the Spero Therapeutics, Inc. 2017 Stock Incentive Plan, as amended (the 2017 Plan), representing an increase of 2,000,000 shares reserved under the 2017 Plan effective September 15, 2022. This registration statement registers additional securities of the same class as other securities for which a registration statement filed on Form S-8 (File No. 333-222060) relating to an employee benefit plan is effective. The information contained in the Registrants registration statement on Form S-8 filed with the Securities and Exchange Commission on December 14, 2017 (File No. 333-222060) is hereby incorporated by reference pursuant to General Instruction E of Form S-8.
PART II
INFORMATION REQUIRED IN THE REGISTRATION STATEMENT
Item 8. Exhibits.
Pursuant to the requirements of the Securities Act of 1933, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Cambridge, Commonwealth of Massachusetts, on November 14, 2022.
SPERO THERAPEUTICS, INC. | ||
By: | /s/ Ankit Mahadevia, M.D. | |
Ankit Mahadevia, M.D. | ||
Chief Executive Officer and President |
Each person whose signature appears below constitutes and appoints Ankit Mahadevia, M.D. and Satyavrat Shukla, and each of them singly, his or her true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution in each of them singly, for him or her and in his or her name, place and stead, and in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8 of Spero Therapeutics, Inc., and to file the same, with all exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting to the attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite or necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that the attorneys-in-fact and agents or any of each of them or their substitute may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
Title |
Date | ||
/s/ Ankit Mahadevia, M.D. Ankit Mahadevia, M.D. |
Chief Executive Officer and President and Director (Principal Executive Officer) |
November 14, 2022 | ||
/s/ Satyavrat Shukla Satyavrat Shukla |
Chief Financial Officer and Treasurer (Principal Financial Officer and Principal Accounting Officer) |
November 14, 2022 | ||
/s/ Milind Deshpande, Ph.D. |
Director | November 14, 2022 | ||
Milind Deshpande, Ph.D. | ||||
/s/ Scott Jackson |
Director | November 14, 2022 | ||
Scott Jackson | ||||
/s/ John C. Pottage, M.D. |
Director | November 14, 2022 | ||
John C. Pottage, M.D. | ||||
/s/ Cynthia Smith |
Director | November 14, 2022 | ||
Cynthia Smith | ||||
/s/ Frank E. Thomas |
Director | November 14, 2022 | ||
Frank E. Thomas | ||||
/s/ Kathleen Tregoning |
Director | November 14, 2022 | ||
Kathleen Tregoning | ||||
/s/ Patrick Vink, M.D. |
Director | November 14, 2022 | ||
Patrick Vink, M.D. |
1 Year Spero Therapeutics Chart |
1 Month Spero Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions